• Publications
  • Influence
Total intravenous anesthesia using remifentanil in extracorporeal shock wave lithotripsy (ESWL). Comparison of two dosages: a randomized clinical trial.
BACKGROUND Extracorporeal Shock Wave Lithotripsy is usually performed in day surgery setting, consequently people who undergo to this procedure need a safe and fast recovery. Conscious sedation withExpand
  • 5
  • 1
Combination of rituximab and nonpegylated liposomal doxorubicin (R‐NPLD) as front‐line therapy for aggressive non‐Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single‐center
The incidence of non‐Hodgkin lymphoma in patients 80 years of age or older is 50 times higher than in 20‐ to 24‐year‐olds. Very elderly patients are often not treated with standard immunochemotherapyExpand
  • 5
  • 1
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II
Rituximab ® provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with SMZL who were eitherExpand
  • 16
  • PDF
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study).
BACKGROUND Mantle cell lymphoma (MCL) has the worst prognosis of B-cell subtypes owing to its aggressive clinical disease course and incurability with standard chemo-immunotherapy. Options forExpand
  • 5
Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real‐world study
In order to assess the efficacy of brentuximab vedotin (Bv) in combination with bendamustine (B) in multiple relapsed or refractory (RR) classic Hodgkin lymphoma (cHL), medical records of 47 patientsExpand
  • 1
Lymphoma R-COMP as a first-line treatment for Splenic Marginal Zone Lymphoma . A Fondazione Italiana Linfomi phase II study
DISCLAIMER: The ideas and opinions expressed in the journal’s Just Accepted articles do not necessarily reflect those of Informa Healthcare (the Publisher), the Editors or the journal. The PublisherExpand
Heterogeneity and Peculiarities Of a Small Series Of Patients Affected By Paroxysmal Nocturnal Hemoglobinuria Treated With Eculizumab
Paroxysmal nocturnal hemoglobinuria (PNH) derives from a non malignant clonal expansion of hematopoietic stem cells (HSCs) harbouring somatic mutations of the X-linked PIG-A gene, leading to theExpand
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice, the Lenamant Study
Mantle cell lymphoma (MCL) is an uncommon type of non- Hodgkin lymphoma (NHL) comprising Disclosures Rusconi:Roche: Honoraria. Zinzani:Gilead: Membership on an entity9s Board of Directors or advisoryExpand
Autologous stem cell transplantation in multiple myeloma.
The treatment of patients with multiple myeloma has changed in the last decades, with an improved median survival of 8-10 years. The current treatment for newly diagnosed multiple myeloma patientsExpand